Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298973 · ClinicalTrials.gov registry record · Phase 4
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
A Phase 4 study of Cataracts, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT01298973 is a Phase 4 study of Cataracts that has completed, run by Innovative Medical. The registered enrollment target is 50 participants, below the 92-participant average among 8 other Cataracts trials with a reported enrollment target (46% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01298973, a Phase 4 study of Cataracts, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Viscoat
Study Locations (2)
Florida
- Florida Eye Microsurgical Institute - Boynton Beach
- Eye Physicians of Central Florida - Maitland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01298973
The ClinicalTrials.gov registry entry for NCT01298973 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 8 other Cataracts trials with a reported enrollment target (46% lower). The listed sponsor is Innovative Medical, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT01298973 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01298973 about?
NCT01298973 is a clinical study titled "Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions". The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.
What is the current status of trial NCT01298973?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2011-01. Estimated completion is 2012-01.
What conditions does trial NCT01298973 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT01298973?
The interventions under investigation include: Saline (DRUG), Viscoat (DRUG).
Who is sponsoring clinical trial NCT01298973?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01298973 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.